RUBCN and prostate carcinoma: Strikingly, prostate cancer patients receiving anti-androgen therapy exhibited a significant decrease in the levels of testicular Rubicon and GATA4 relative to a tumor-free patient or prostate cancer patients who did not receive such treatment (Fig 7E–7G).